Evidence map›Paper›PMID 21949680›Full record

ArticlePloS one2011

South American Plasmodium falciparum after the malaria eradication era: clonal population expansion and survival of the fittest hybrids.

Sean M Griffing, Tonya Mixson-Hayden, Sankar Sridaran, Md Tauqeer Alam, Andrea M McCollum, César Cabezas, Wilmer Marquiño Quezada, John W Barnwell, Alexandre Macedo De Oliveira, Carmen Lucas and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
7.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 84 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Malaria control and the unexpected spread of diagnostic-resistantbioRxiv : the preprint server for biology · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Molecular Surveillance of Artemisinin-ResistantInternational journal of environmental research and public health · 2024
    Article
  11. Article
  12. Article
  13. Molecular epidemiology of continuedFrontiers in tropical diseases · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Sean M GriffingMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Tonya Mixson-Hayden
Sankar Sridaran
Md Tauqeer Alam
Andrea M McCollum
César Cabezas
Wilmer Marquiño Quezada
John W Barnwell
Alexandre Macedo De Oliveira
Carmen Lucas
Nancy Arrospide
Ananias A Escalante
David J Bacon
Venkatachalam Udhayakumar
Centers for Disease Control and Prevention · USInstituto Nacional de Salud · PECenter for Global Health · USNaval Medical Research Unit Six · PEArizona State University · USAssociation of Public Health Laboratories · USAtlanta Research and Education Foundation · USDivision of Parasitic Diseases and Malaria · US

Funding

A Global Comparative Study of the Evolution of Antimalarial Drug ResistanceR01GM084320 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI ESCALANTE, ANANIAS ALBERTO · 2008 to 2011
$1.4M
NIGMS NIH HHS R01 GM084320NIGMS NIH HHS R01GM084320
6 · The paper itself

Abstract

Malaria has reemerged in many regions where once it was nearly eliminated. Yet the source of these parasites, the process of repopulation, their population structure, and dynamics are ill defined. Peru was one of malaria eradication's successes, where Plasmodium falciparum was nearly eliminated for two decades. It reemerged in the 1990s. In the new era of malaria elimination, Peruvian P. falciparum is a model of malaria reinvasion. We investigated its population structure and drug resistance profiles. We hypothesized that only populations adapted to local ecological niches could expand and repopulate and originated as vestigial populations or recent introductions. We investigated the genetic structure (using microsatellites) and drug resistant genotypes of 220 parasites collected from patients immediately after peak epidemic expansion (1999-2000) from seven sites across the country. The majority of parasites could be grouped into five clonal lineages by networks and AMOVA. The distribution of clonal lineages and their drug sensitivity profiles suggested geographic structure. In 2001, artesunate combination therapy was introduced in Peru. We tested 62 parasites collected in 2006-2007 for changes in genetic structure. Clonal lineages had recombined under selection for the fittest parasites. Our findings illustrate that local adaptations in the post-eradication era have contributed to clonal lineage expansion. Within the shifting confluence of drug policy and malaria incidence, populations continue to evolve through genetic outcrossing influenced by antimalarial selection pressure. Understanding the population substructure of P. falciparum has implications for vaccine, drug, and epidemiologic studies, including monitoring malaria during and after the elimination phase.

Indexed as

AntimalarialsATP-Binding Cassette, Sub-Family C ProteinsDihydropteroate SynthaseDrug ResistanceEpidemicsGene FrequencyGenotypeGeographyHaplotypesHumansLinkage DisequilibriumMalaria, FalciparumMembrane Transport ProteinsMicrosatellite RepeatsPeruPhylogenyAntimalarialsATP-Binding Cassette, Sub-Family C ProteinsDihydropteroate SynthaseMdr1 protein, Plasmodium falciparumMembrane Transport ProteinsPfCRT protein, Plasmodium falciparumProtozoan ProteinsTetrahydrofolate Dehydrogenase

Identifiers

PMID21949680
PMCPMC3174945
OpenAlexW2063566928

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.